Expert Practice℠ in Gynecologic Malignancies
prIME Downloadable Slides
prIME Downloadable Slides

Expert Practice℠ in Gynecologic Malignancies

Not a member of My prIME? Join now for instant access.

View downloadable slides from our case-based program, Expert Practice℠ in Gynecologic Malignancies, to enhance your knowledge of the latest therapeutic strategies for gynecologic malignancies, including newly-diagnosed and recurrent ovarian cancer, cervical cancer, and uterine leiomyosarcoma.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 24, 2017

Expiration Date

Oct 24, 2018

Featured Expert

  • Eric Pujade-Lauraine, MD, PhD, Centre Hospitalier Universitaire Hôtel-Dieu, Paris, France

Featured Topic

Keynote lecture—Immunotherapy: An evolving strategy in gynecologic cancers

Featured Expert

  • Jalid Sehouli, MD, PhD, University Hospital Charité–Campus Virchow Klinikum, Berlin, Germany

Featured Topic

Newly diagnosed advanced ovarian cancer: Selecting front-line therapy

Featured Expert

  • Nicoletta Colombo, MD, University of Milan–Bicocca, European Institute of Oncology, Milan, Italy

Featured Topic

Recurrent ovarian cancer (platinum therapy–free interval [TFI-p] 6-12 months): Evaluating treatment options

Featured Expert

  • Antonio González-Martín, MD, Clínica Universidad de Navarra, Madrid, Spain

Featured Topic

Treatment of recurrent ovarian cancer (TFI-p>12 months) and the role of maintenance therapy

Featured Expert

  • Ignace Vergote, MD, PhD, University Hospitals Leuven, Leuven, European Union

Featured Topic

Platinum-resistant ovarian cancer: Is there a light at the end of the tunnel?

Featured Expert

  • Philipp Harter, MD, PhD, Kliniken Essen-Mitte, Essen, Germany

Featured Topic

Uterine leiomyosarcoma: Diagnostic and therapeutic considerations

Featured Expert

  • Nicoletta Colombo, MD, University of Milan–Bicocca, European Institute of Oncology, Milan, Italy

Featured Topic

Optimizing management of advanced cervical cancer

This educational activity is designed for European gynecologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Describe the rationale and ongoing trials evaluating immunotherapies for the treatment of gynecologic cancers
  • Select optimal management for newly diagnosed advanced ovarian cancer, including the use of neoadjuvant chemotherapy and targeted therapy in the front-line therapy setting
  • Explain the role of predictive biomarkers such as BRCA mutations and homologous recombination deficiency (HRD) score for treatment with PARP inhibitors
  • Identify patients with relapsed ovarian cancer who may benefit from secondary debulking surgery, targeted maintenance therapy, or use of platinum-free chemotherapy
  • Describe management of treatment-related adverse events, including optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV)
  • Evaluate treatment options for patients with uterine sarcoma and other uterine cancers
  • Assess standard and emerging therapies for advanced cervical cancer

This educational activity is supported by grants from ImmunoGen, Inc.; PharmaMar S.A.; and Tesaro.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Colombo has disclosed that she has received honoraria or consultation fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer Inc., PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr González-Martín has disclosed that he has received honoraria or consultation fees from Amgen, AstraZeneca, Clovis, PharmaMar, and Roche. He has also participated in sponsored speaker bureaus for AstraZeneca, PharmaMar, and Roche. Dr González-Martín has also served as a speaker and in an advisory role for Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harter has disclosed that he has received grants or research support from AstraZeneca, Clovis, Lilly, PharmaMar, Roche, and Sotio, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pujade-Lauraine has disclosed that he has received honoraria or consultation fees from AstraZeneca, Clovis, Pfizer, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sehouli has disclosed that he has received grants or research support from AstraZeneca, Lilly, and Roche. He has also received honoraria or consultation fees from AstraZeneca, Clovis, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vergote has disclosed consulting on advisory boards for Advaxis Inc, Amgen Inc, AstraZeneca, Bayer Pharma AG, Cerulean Pharma Inc, Debiopharma International SA, Eli Lilly, F. Hoffmann-La Roche Ltd, GCI Health, Genmab A/S, Immunogen Inc, Janssen-Cilag, Mateon Therapeutics Inc, Morphotek, Nektar Therapeutics, MSD Belgium BVBA, Novartis Pharma AG, Novocure GMBH, Oncoinvent AS, Oxigene Inc, Pfizer, Roche, Theradex, and Vifor Pharma. Dr Vergote has also disclosed that he has performed contracted research via KU Leuven, that he has received grant support (corporate-sponsored research) from Amgen and Roche, and that he has received support for accommodation and travel expenses from Elsevier, Tesaro, and Theradex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.